

ThinkEquity,
A Division of Fordham Financial Management, Inc
17 State Street, 22nd Floor
New York, New York 10004

November 12, 2020

VIA EDGAR

United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

Re: Inhibikase Therapeutics, Inc. (the “Company”)
Registration Statement on Form S-1, as amended (the “Registration Statement”)
File No. 333-240036

Ladies and Gentlemen:

On November 6, 2020, ThinkEquity, a division of Fordham Financial Management, Inc. (“**ThinkEquity**”), as representative of the underwriters of the offering, joined in the request of the Company that the effective date of the above-referenced Registration Statement on Form S-1 be accelerated so as to permit it to become effective on Tuesday, November 10, 2020, at 5:00 p.m. (Eastern Time), or as soon thereafter as practicable. The undersigned, on behalf of ThinkEquity, hereby withdraws such request.

Very truly yours,

ThinkEquity,
a division of Fordham Financial Management, Inc.

By: /s/ Eric Lord
Name: Eric Lord
Title: Head of Investment Banking

cc: Leslie Marlow, Esq.
Patrick J. Egan, Esq.
